Crisnatol (BW-A770U) is an experimental anticancer agent.[1] A Phase I clinical trial was published in 1999.[2]

References

  1. ^ U.S. patent 4,719,046
  2. ^ Villalona-Calero MA, Petit T, Kuhn J, Cobb P, Kraynak M, Eckhardt SG, et al. (November 1999). "A phase I and pharmacological study of protracted infusions of crisnatol mesylate in patients with solid malignancies". Clinical Cancer Research. 5 (11): 3369–78. PMID 10589747.